New combo therapy shows promise for advanced nose cancer

This study tests a treatment plan for people with stage IVA nasopharyngeal cancer (a type of nose and throat cancer). Participants receive a combination of the immunotherapy drug pembrolizumab and chemotherapy before and during radiation, followed by maintenance pembrolizumab for up to a year. The goal is to see if this approach improves how long the cancer stays away. The study enrolled 43 adults and is no longer recruiting new participants.